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ABSTRACT
The Wistar Kyoto (WKY) rat and the spontaneously hypertensive
(SHR) rat inbred strains are well-established models for human
crescentic glomerulonephritis (CRGN) and metabolic syndrome,
respectively. Novel transgenic (Tg) strains add research
opportunities and increase scientific value to well-established rat
models. We have created two novel Tg strains using Sleeping Beauty
transposon germline transgenesis, ubiquitously expressing green
fluorescent protein (GFP) under the rat elongation factor 1 alpha
(EF1a) promoter on the WKY and SHR genetic backgrounds. The
Sleeping Beauty system functioned with high transgenesis efficiency;
75% of new rats born after embryo microinjections were transgene
positive. By ligation-mediated PCR, we located the genome
integration sites, confirming no exonic disruption and defining a
single or low copy number of the transgenes in the new WKY-GFP
andSHR-GFP Tg lines.We report GFP-bright expression in embryos,
tissues and organs in both lines and show preliminary in vitro and
in vivo imaging data that demonstrate the utility of the new GFP-
expressing lines for adoptive transfer, transplantation and fate
mapping studies of CRGN, metabolic syndrome and other traits for
which these strains have been extensively studied over the past four
decades.
KEY WORDS: GFP, SHR, WKY, Rat, Transgenics
INTRODUCTION
The rat has long been an important physiological model of complex
human disease (Aitman et al., 2008; Iannaccone and Jacob, 2009).
Twowell-studied strains, both originating fromWistar stock, are the
Wistar Kyoto (WKY) and spontaneously hypertensive (SHR)
inbred rats (Kurtz andMorris, 1987; Okamoto and Aoki, 1963). The
WKY rat has been studied extensively as a model of crescentic
glomerulonephritis (Aitman et al., 2006; Atanur et al., 2013;
Behmoaras et al., 2008, 2015; D’Souza et al., 2013; Kanno et al.,
1998; Sado et al., 1984; Smith et al., 2007), as a control for the SHR
strain and as a model of depression and behavioural abnormalities
(Will et al., 2003). The SHR strain has been widely used as a model
of the human hypertension and metabolic syndrome as well as a
large number of other pathophysiological phenotypes including
cardiac hypertrophy and failure, insulin resistance and defects in
lipid metabolism (Aitman et al., 1999, 1997; Lepretre et al., 2004;
Pravenec et al., 2008; Yamori and Okamoto, 1974).
Both inbred strains are well characterised, with 199 and 197
quantitative trait loci (QTLs) mapped, respectively, in WKY and
SHR (Shimoyama et al., 2015), and whole genome sequences of
both strains now publically available (Aitman et al., 2008; Atanur
et al., 2010, 2013; Hubner et al., 2005; Shimoyama et al., 2015).
With the advent of gene targeting technologies that are suited to use
in rats, including zinc finger nucleases (ZFNs) (Geurts et al., 2009),
transcription activator-like effector nucleases (TALENs) (Tesson
et al., 2011), clustered regularly interspaced short palindromic
repeats (CRISPRs) (Shen et al., 2013) and Sleeping Beauty (SB)
transposon system (Ivics et al., 2009; Kitada et al., 2007; Mátés,
2011), increasing numbers of new transgenic (Tg), knockout and
knock-in rat models have been created to elucidate the functional
basis of disease phenotypes (Jacob et al., 2010).
Fluorescence imaging for in vitro and in vivo analysis of
biological processes, combined with GFP Tg models, are valuable
reagents for translational research. Tg models reporting ubiquitous
enhanced green fluorescent protein (GFP) have been described in
inbred rats mostly under the control of the chimeric CAG
(cytomegalovirus enhancer, chicken β-actin enhancer-promoter,
and intronic sequences from rabbit β-globin) promoter, using
classical transgenesis (Hakamata et al., 2001), lentivirus
integrations (Michalkiewicz et al., 2007) and Sleeping Beauty
(Katter et al., 2013). However, there are shortcomings in some of
these approaches. Classical transgenesis (Charreau et al., 1996;
Mullins et al., 1990) has low efficiency and is likely to insert
concatemer transgene copies in the genome. This can predispose to
gene silencing and a high frequency of mosaic founders (Bishop and
Smith, 1989; Garrick et al., 1998; Whitelaw et al., 1993). Lentivirus
integrations have high efficiency, but also have drawbacks including
triggering of transgene silencing by epigenetic regulation and
production of mosaic founders. As well as limitations in transgene
size, lentiviruses can cause embryo toxicity resulting from
preferential transgene insertion in endogenous genes (Ellis, 2005;
Hofmann et al., 2006; Lois et al., 2002; Wolf and Goff, 2009).
This paper describes the creation of two new ubiquitously
expressing GFP models in WKY and SHR inbred rat lines by
combining a highly efficient transgenic system and a strong
mammalian endogenous promoter. We took advantage of the
Sleeping Beauty (SB) transposon system that randomly integrates
single copies or low copy number of a gene of interest (Ivics et al.,
2014; Mátés, 2011). We opted for the rat elongation factor 1 alpha
(EF1a) promoter (Kim et al., 1990; Mizushima and Nagata, 1990).
The rat EF1a gene encodes an isoform of the alpha subunit of the
elongation factor-1 complex, which is responsible for the enzymaticReceived 25 November 2015; Accepted 13 January 2016
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delivery of aminoacyl tRNAs to the ribosome (Sasikumar et al.,
2012) and its promoter has been successfully used in gene therapy
studies as a non-viral alternative to the cytomegalovirus promoter
(Gill et al., 2001; Serafini et al., 2004; Zheng and Baum, 2005). We
report GFP expression in embryos, tissues, ex vivo cell cultures and
in an in vivo imaging model of bone marrow transplantation to
validate these lines as useful tools for translational research.
RESULTS
Microinjection results
Seventy-five percent of newborn pups after microinjections were
GFP-positive by direct inspection under UV light and by PCR. PCR
assay results corresponded exactly to GFP expression by direct
inspection in both WKY-GFP and SHR-GFP rat lines (Table 1).
Two positive F0 founders from each strain were crossed to wild
type to confirm transgene germ line transmission. All F0 founders
transmitted the transgene. Only one high-GFP-expresser F0 per
strain was used to derive each transgenic (Tg) rat line. Both lines
showed normal growth, were able to reproduce and germline
transmit the transgene, and after more than five generations, GFP
expression was maintained without any sign of transgene silencing.
Examination of the GFP integration site
Ligation-mediated PCR (LMPCR) protocol (Ivics et al., 2014) was
used to locate the transgene integration site in the host genome. GFP
transgene insertion sites were located using Ensembl genome
browser, Rat (Rnor_6.0).
Two integration sites were identified in the WKY-GFP
founder of the Tg line on chromosome 8:28170658 and
chromosome 1:276465837, both located in intronic gene
areas, Jam3 (ENSRNOG00000009149) intron 1 and Vti1a
(ENSRNOG00000042786) intron 6, respectively (Fig. 1C).
The Jam3 intron 1 is 51,319 bp long, and the transgene
resides at 37.8 kb from exon 1 and 13.5 kb from exon 2. In
Vti1a intron 6, 102,565 bp long, the transgene is located at
81.4 kb from exon 5 and 21.1 kb from exon 6.
One single location was identified in the SHR-GFP founder of the
Tg line on chromosome 5:108698150, an intergenic area where the
closest gene, Zfp353 (ENSRNOG00000050804), is located at
47.9 kb downstream (Fig. 1C).
GFP expression in embryos, tissues and blood
To examine the level of GFP expression in tissues from Tg WKY
and SHR rats, blood, cells and organs were processed for
fluorescence microscopy. Fig. 2 shows representative examples of
GFP expression in embryonic day (E)4.5 early blastocyst embryos
from homozygote WKY-GFP female crossed with wild-type WKY
male. All embryos were GFP-bright that sustained for at least 12 h in
culture (Fig. 2, lower panel). Similar expression was noted inWKY-
GFP homozygotes and SHR-GFP rats (data not shown).
We next isolated brain, eye, salivary glands, thymus, heart, lung,
liver, kidney, adrenal glands, gut, pancreas, spleen, and quadriceps
from wild-type (SHR), WKY-GFP and SHR-GFP rats. All organs
displayed bright GFP expression with some differences in GFP
intensity between and within organs (Fig. 3; Fig. S1). In general,
GFP intensity was moderately less in SHR rats, although both
strains expressed GFP in all organs and tissues investigated (Fig. 3).
Interestingly, small variations in GFP expression were observed in
heart, kidney, thymus and brain tissue, localised to specific areas
within the organs (Fig. 3). This might reflect differences in EF1a
expression in different cell types.
GFP intensity was also maintained after tissue histological
processing. Kidney, liver, spleen and thymus were processed for
frozen sectioning and stained for GFP and DAPI expression. All
tissues were GFP-bright, with some differences in GFP expression
across the tissue (Fig. S2).
We next analysed GFP expression in blood cell populations using
flow cytometry. All blood leukocyte populations, based on either
SSChigh or SSClow cells, expressed similar amounts of GFP intensity
in both WKY-GFP and SHR-GFP rats (Fig. 4A). However, after
gating for either granulocytes (Gran), MHC class II (MHC-II) or
CD68 there were noticeable differences in GFP expression on some
subpopulations in SHR-GFP rats (Fig. 4B). Similar data was noted
for WKY-GFP rats (data not shown). CD68negGranposMHC-IIhigh
cells, which are most likely lymphocyte and some granulocyte
populations, expressed the highest level of GFP (Fig. 4B), whereas
CD68pos (monocytes) are GFP intermediate, and GFPlow-
expressing cells are within Granpos and MHC-IIhigh populations
(Fig. 4B). The differences might reflect EF1a expression in different
circulating subpopulations.
Bone marrow-derived macrophage culture in vitro
To examine if GFP could be sustained in primary cell culture
passage, which would be useful for downstream experimental
applications, we examined GFP expression in bone marrow-derived
macrophages (BMDM). BMDMs cultured over 5 and 10 days
sustained high GFP expression, as detected by fluorescence
microscopy (Fig. 5A). There was no difference in WKY-GFP or
SHR-GFP BMDM GFP expression, and similar amounts of GFP
were expressed between 5 and 10 days (Fig. 5A). This indicates that
within proliferating macrophage cultures, EF1a activity and
consequently GFP intensity is maintained in daughter cells.
In vivo bone marrow chimeras and intravital microscopy
To further examine the utility of Tg rat GFP lines in potential disease
models and in vivo applications, we examined GFP intensity in
WKY-GFP bone marrow chimera experiments using intravital
microscopy. WKY-GFP bone marrow transfer was performed in
WKY recipients and the kidney cortex exposed for confocal
imaging. Fig. 5B shows that GFP-bright cells can be seen located at
the endothelial interface.
DISCUSSION
The potential of rat models for understanding basic biology and
human health and disease (Aitman et al., 2008) has increased owing
to availability of new gene targeting tools applicable to the rat (Atanur
et al., 2013; Jacob et al., 2010) and communal efforts to increase and
refine rat genomic resources. Important aims of creating Tg rat
Table 1. Overall transgenesis efficiency by the Sleeping Beauty transposon system
No. of zygotes surviving microinjection
and transferred to recipients No. of pregnant recipients
Efficiency of transposon integration
Per newborn Per injected zygote
WKY-GFP 22/85 (25.8%) 1/1 (100%) 3/4 (75%) 3/22 (13.6%)
SHR-GFP 96/270 (35.5%) 3/3 (100%) 6/8 (75%) 6/96 (6.25%)
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models, or any Tg animal model, are to achieve high transgenesis
efficiency with strong and permanent expression of the gene of
interest through generations, with high efficiency to minimise use of
resources and animal numbers. The efficiency of transgenesis has
increased in recent years as a result of development and refinement of
new systems, from low efficiency of classical transgenesis by
microinjection of naked DNA (Charreau et al., 1996; Filipiak and
Saunders, 2006) to higher efficiency with retroviral transgenesis and
the latest lentivirus vectors (Michalkiewicz et al., 2007). The Sleeping
Beauty transposon system has advantages for germline transgenesis
as a simpler and safer delivery system, matching or exceeding other
approaches. This approach, with a single copy of a permanent
insertion in the genome, leads to preferential intergenic integrations
and is less prone to silencing (Ivics et al., 2014; Katter et al., 2013;
Mátés, 2011; Mátés et al., 2009; Park, 2007).
We have created two new transgenic lines, on the WKY and SHR
genetic backgrounds, that display and take advantage of many of
these characteristics. In our experiments, 75% of F0 newborn pups
were transgene-positive (Table 1), one of the highest transgenesis
efficiencies reported. Such efficiency, in our case, seems
independent of the SHR or WKY genetic rat background. In our
Tg models, GFP expression seems to be independent of integration
site and genomic background and dependent on promoter
endogenous/native activity. Further, expression was transmitted
unchanged through more than five generations of breeding and
through 5-10 days of in vitromacrophage culture, demonstrating the
stability of expression from the transgene constructs integrated into
the germline genome. Finally, the high level of GFP expression was
shown to have created a suitable platform for cell fate tracking
through intravital microscopy and confocal imaging.
Avoiding the production of mosaic founders is an important way
to minimise cost and increase functional efficiency. Sleeping
Beauty is a plasmid/mRNA-based method where the transposase
mRNA does not need embryonic genome activation. In rats this
begins at the four-cell stage and only needs translation of the
transposase mRNA in the early embryo stages. This system largely
avoids the creation of mosaic founders (Mátés, 2011). This is
superior to lentivirus transgenesis where reverse transcription is
necessary and where viral infection and integration can continue
with embryonic development (Park, 2007). The transmission of the
transgene over five generations in our lines excludes the possibility
of mosaicism in the selected founders of our established WKY and
SHR lines.
The Sleeping Beauty transposon system randomly integrates the
gene of interest in the genome with a bias to intergenic integration
(Ammar et al., 2012; Grabundzija et al., 2010; Katter et al., 2013;
Moldt et al., 2011). We show in our new GFP Tg rat models, by
locating and verifying the integration locus sites, that there was no
Fig. 1. GFP transgenic rat design.
(A) Schematic plasmid
representation. Rat elongation factor
1 alpha promoter (rEF1a) replaces
CAG promoter (CAGGS). IR, inverted
repeats; GFP, green fluorescent
protein cDNA. (B) Photograph of
WKY-GFP pups (left) and adult (right)
rats under excitation light 489 nm,
showing wild-type and GFP Tg
animals. (C) Schematic genome
locus showing TA integration sites
location of transgene for SHR-GFP in
chromosome 5, and WKY-GFP in
chromosome 1 and 8. Genomic
sequence (left junction) in capitals
and transgene in lowercase, dotted
horizontal line refers to intergenic,
continuous black line to intronic, and
vertical blocks to exonic sequences.
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functional gene disruption resulting from exon insertion. We
confirmed individual transgene integration by locus-specific PCR,
making possible the isolation of each integration by selective
breeding and establishing unique locus integration per rat line. In the
SHR inbred background the insertion position was at chromosome
5:108698150, an intergenic locus 47.9 kb upstream of gene Zfp353.
In such a location, using the rat genome information available
(Rnor_6.0), we cannot foresee any biological impairment. In the
WKY inbred background the two located integration sites were
intronic, one on chromosome 1:276465837, intron 6 (102,565 bp
long) of gene Vti1a (vesicle transport through interaction with
t-SNAREs 1A) and the other on chromosome 8:28170658, intron 1
(51,319 bp) of gene Jam3 ( junctional adhesion molecule 3).
Regulatory splicing elements can be found in the intron up to
300 bp from the exon-intron border (Barash et al., 2010). Our
intronic integrations are far away from these areas, being ∼13.5 kb
from the closest exon-intron border. Therefore, effects on the
splicing machinery would not be foreseen although interference
resulting from Tg insertion in introns, which regulate gene
expression by noncoding RNA molecules, intron-mediated
enhancement or by other intronic regulatory functions, cannot be
completely excluded.
To ensure strong and permanent expression, many factors are
necessary, including a strong promoter and fortuitous integration in
the genome to avoid transgene silencing (Kioussis and Festenstein,
1997). The selection of promoter was fundamental to accomplish this
goal. We decided to move away from the most-used, the chimeric
exogenous CAG promoter, because it contains the cytomegalovirus
enhancer sequence and because of its viral nature could trigger
silencing mechanisms affecting GFP expression. Moreover, although
CAG promoters are ubiquitous, it has been reported there are different
expression patterns within different tissues and within different
transgenic models, from high expression to low or no expression
(Hakamata et al., 2001; Inoue et al., 2005; Katter et al., 2013;
Michalkiewicz et al., 2007; Murakami and Kobayashi, 2012; Popova
et al., 2008; Takeuchi et al., 2003). We therefore opted for an
endogenous promoter to maximise the likelihood of permanent
expression and escape from gene silencing. Most promoters that have
been used have some disadvantages. For example, rat transgenic
models using ubiquitin C (van den Brandt et al., 2004),
phosphoglycerate kinase 1 (PGK1) (Remy et al., 2010) and Rosa26
(Montanari et al., 2014) promoters report chimeric expression.
Potential promoter candidates were compared using the online
BioGPS application (http://biogps.org) where the tissue-specific
pattern of mRNA expression of their endogenous driven protein is
quantified.We hypothesized that the expression of GFPwill mimic, at
least to an extent, the reported expression of our gene of interest.
Eukaryotic elongation factor 1 alpha 1 (EEF1A1), also known as
elongation factor 1 alpha (EF1a) has one of the most wide-ranging
tissue expression patterns, with the highest median (M=10,426.3),
followed by ubiquitin C (M=4620.6) and PGK1 (M=4.5). One
possible weakness of EF1a is the low expression in heart and skeletal
muscle tissues. However, given the near ubiquitous expression, we
selected the EF1a promoter for our Tg models.
In our Tg models, GFP expression seems to be independent of
integration site and genomic background and dependent on
promoter endogenous/native activity. We visually confirmed that
GFP expression follows the pattern of EF1a mRNA expression,
with a markedly lower expression in the heart, in both SHR and
WKY rats, implying possibly that the EF1a promoter is the main
determinant in these strains of the level of tissue GFP expression.
It would be interesting to perform further studies to quantify gfp
mRNA versus EF1a mRNA in tissues to assess transcriptional
correlation. If true, these models could be used as an EF1a
expression reporter, and also as an EF1a canonical function assay
to deliver aa-tRNA to ribosomes in mRNA translation. It could
well be a reporter for cellular translation levels. The difference in
GFP intensity between the SHR and WKY Tg models could be a
result of transgene copy, SHR with a single copy shows relatively
lower expression of GFP than WKY with two integrations.
Finally, heterogeneous GFP expression within a tissue, such as the
brain, might reflect a differing chromatin state of the integration
site. One hypothesis could be that, because the EF1a promoter is
essential in cellular protein translation, integration could make the
chromatin more accessible in particular cell types if these loci are
normally closed when translation occurs. Further work is needed
Fig. 2. GFP expression in embryos. Female WKT-
GFP rats were crossed with wild-type WKYmale rats
and one-cell embryos removed and imaged under
confocal microscope. Representation of three
experiments from one-cell embryos at E4.5 and E4.5
plus 12 h showing bright field (BF) images and
expression of GFP. Scale bar: 15 μm (top panel);
40 μm (bottom panel).
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to confirm whether these models reflect EF1a expression in
specific tissues and/or chromatin state after integration.
In summary, we have created two novel Tg models expressing
ubiquitous green fluorescent protein in WKY and SHR inbred rat
lines to support in vivo and ex vivo studies in cell tracking, tissue and
organ transplantation for further elucidation of the complex disease
traits of human crescentic glomerulonephritis (CRGN) andmetabolic
syndrome, respectively. Our preliminary study using real-time
imaging of kidney leukocyte-endothelial interactions in WKY-GFP
bone marrow chimeras confirms the utility of GFP transgenic rats for
fluorescent imaging. Both novel Tg lines have considerable value for
future translational research in the scientific community.
MATERIALS AND METHODS
All animals were housed in individually ventilated cages. All procedures
were carried out according to the institutional guidelines for the care and use
of experimental animals and the ARRIVE guidelines. Animal studies were
approved by the UK Home Office.
Generation of ubiquitous GFP WKY and SHR rats using Sleeping
Beauty transgenesis
Preparation of the transposon donor plasmid and microinjection
Schematic of plasmid is shown in Fig. 1A. The CAGGS promoter in pSB
IR-DR(L)-CAGGS-eGFP-pA-IR-DR(R) plasmid was replaced with the
native rat elongation factor-1 alpha promoter (EF1a) from pDRIVE-rEF1α
(InvivoGen). Fragment PstI-NcoI containing the EF1a promoter was
Fig. 3. GFP expression in organs and tissues. Wild type (from
SHR strain), WKY-GFP and SHR-GFP rats were examined for
gross GFP expression in dissected heart, brain, kidney, eyes,
thymus, gut, liver, spleen and muscle tissues. Whole organ
extracts were mounted for white light (left three panels) and stereo-
fluorescence imaging (right three panels). Scale bar: 2 mm.
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blunted and inserted into the NotI-MluI blunted backbone. Screening for
‘sense’ orientation was by EcoRI digestion. Functional elements of the
Sleeping Beauty construct were confirmed by sequencing. The SB100x
transposase was prepared following protocol by Mátés (2011).
Synchronization of oestrus cycle in rat recipients
The foster females aged 8 to 12 weeks were injected intraperitoneally (i.p.)
with 40 μg of luteinizing hormone-releasing hormone (LH-RH) agonist
4 days prior to mating. On the day of mating, the recipients were
individually placed with vasectomised males. The following day, the
females were de-mated and examined for the presence of copulation plug.
The females presenting a plug were used as embryo recipient for embryo
transfer surgery on the same day.
Embryo preparation and microinjection
Six SHR and nineWKY females aged 4 to 6 weeks old were used as embryo
donors. Two days prior to mating, females were injected i.p. with 30 IU of
pregnant mare serum gonadotropin (PMSG). On the day of mating, the
Fig. 4. GFP expression in blood leukocyte populations. Anticoagulated blood from wild-type, WKY-GFP and SHR-GFP rats were examined for GFP
expression with or without fluorescent-labelled antibodies using flow cytometry. (A) Histograms of GFP expression in SSChi and SSClow populations. (B) Lower
panels: dot plots of GFP expression versus granulocyte (Gran)-, MHC class II (MHC-II)- or CD68-positive populations, in cells gated by R1 (upper panel).
Representative of at least n=4 rats.
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females were injected i.p. with 40 IU of human pregnancy urine chorionic
gonadotropin (HCG) and placed individually with SHRorWKYmales. The
following day, the females were separated, culled and the oviducts removed.
The oviducts were then placed in M2 media (Sigma) and the ampulla torn to
release single-cell embryos. Hyaluronidase was then added to the media to
remove the cumulus cells. The embryos were collected and cleaned using a
mouth pipette. The fertilized embryos were transferred fromM2 to KSOMaa
media (Zenith Biotech) and left in the incubator at 37°C, 5% CO2 until they
were used for pronuclear injections and embryo transfer (20-40 embryos per
female) using standard protocols (Filipiak and Saunders, 2006; Geurts et al.,
2009). Briefly, pronuclear injection of mixed donor plasmid (0.4 ng/μl) and
mRNA SB100X transposase (5 ng/μl) was performed in WKY and SHR rat
one-cell embryos. Injected embryos were transferred to the oviduct of day-
0.5 pseudopregnant rats and then replaced into Sprague Dawley rat
recipients by embryo transfer surgery.
Screening of GFP-positive pups
Selected F0 founders were crossed with wild types; F1 were screened by
PCR and GFP-positive animals were further screened for GFP expression in
blood to choose high expressers for breeding. Genomic DNAwas extracted
from ear clips by overnight proteinase K digestion at 56°C and precipitated
next day with isopropanol. PCR with two primer pairs was performed to
detect 343 bp actin fragment as control and 180 bp GFP fragment as
transgene positive: DNA_rat_bActin_F: 5′-TGTGTTGTCCCTGTATGC-
CTCT-3′; DNA_rat_bActin_R: 5′-ATTGCCGATAGTGATGACCTGA-
3′; GFP_F: 5′-GGCACCTACCCCAGCGGCTA-3′; GFP_R: 5′-CCGGT-
GCCCACCACCTTGAA-3′.
PCR cycle conditions were: 95°C for 2 min, 30 cycles of 95°C for 30 s,
60°C for 30 s, and 72°C for 30 s with a final 5-min elongation at 72°C. Tail
blood was collected into lithium-heparin microvette tubes and GFP blood
expression was assessed using an AccuriC6 (BD Biosciences) flow
cytometer (see ‘Detection of GFP expression’ below). Whole-animal GFP
expression was confirmed under an excitation light (489 nm) (Fig. 1B).
Integration site identification and locus confirmation
Ligation-mediated PCR (LMPCR) (Ivics et al., 2014) was used to locate the
transgene integration site in the host genome. We designed primers to
combine with Tbal 5′-CTTGTGTCATGCACAAAGTAGATGTCC-3′
from the LMPCR protocol to verify individual transgene integration by
locus-specific PCR: Ch1_is_F: 5′-GACACATCCCTTGCTGTGGA-3′;
Ch1_is_R: 5′-GCTATAACAAAGGGGACAGGCT-3′; Ch5_is_F: 5′-CT-
CCAGCTTGCTTCTTGGGA-3′; Ch5_is_R: 5′-ACTGCACCCCAGAA-
AAAGCA-3′; Ch8_is_F: 5′-GAAACACTGCACGTGGTGAC-3′; Ch8_
is_R: 5′-TCTCTTCCCACAGCCTTTCC-3′.
Detection of GFP expression
Embryos
E4.5 embryos were collected and carefully placed in glass-bottom petri dishes
for confocal imaging, using a Leica Sp5 microscope. Some embryos at E4.5
were harvested and cultured overnight (12 h) in M2 media before imaging.
Organs
Brain, eye, salivary gland, thymus, heart, lung, liver, kidney, adrenal gland,
gut, pancreas, spleen and quadraceps were dissected, washed, fixed (4%
PFA 30 min) and mounted on open glass slides for imaging using a Leica
MZ16F fluorescence stereoscope and Leica camera DFC420C. For some
organs, longitudinal dissection was used to show GFP intensity of inner
organ structures. In addition, kidney, liver, spleen and thymus gross
dissections were embedded in OCT and 2-μm frozen sections mounted onto
slides using hard set mounting media with DAPI (Vectashield). Sections
were imaged using an upright fluorescent microscope (Olympus) for GFP
and DAPI.
Fig. 5. GFP expression in BMDM and intravital
microscopy. (A) Bone marrow-derived macrophages
(BMDM) were harvested and cultured for 5 or 10 days and
intensity of GFP examined in WKY-GFP and SHR-GFP
rats. Scale bar: 75 μm. (B). WKY rats underwent irradiation
and bone marrow transplant from aWKY-GFP donor. After
successful chimerisation, kidney cortex was imaged after
injection of 70 kDa fluorescent dextran under anaesthesia.
Snapshot is shown of GFP-positive cells interacting with
endothelial surfaces within the kidney (arrows).
Representative of at least n=4 rats. Scale bar: 40 μm.
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Blood
Blood was collected into lithium-heparin microvette tubes from tail bleeds.
Red blood cells were lysed (155 mM NH4Cl, 12 mM NaHCO3, 100 mM
EDTA) and leukocytes washed in PBS before permeabilisation (fix-Perm
kit, Invitrogen) and incubation with antibodies against rat Gran-PE (HIS48),
MHC-II-perCP (HIS19) and CD68-Alexa Fluor 700 (ED1) (all 1:50;
BioLegend). Cells were analysed by flow cytometry using an AccuriC6
(Becton Dickinson) with appropriate colour compensation and gates set to
unstained cells.
Culture of bone marrow-derived macrophages
Rat bone marrow-derived macrophages were isolated from femurs and
differentiated using RPMI 1640 supplemented with 10% fetal bovine serum
(Hyclone) and 5 ng/ml Rat M-CSF (Peprotech) as previously described
(D’Souza et al., 2013). Cells were cultured in 12-well plates for 5 or 10 days
at 37°C, 5% CO2 and GFP fluorescence images were taken using confocal
microscopy.
Intravital microscopy
To examine utility of GFP Tg rats for translational work, we tested the real-
time imaging of kidney leukocyte-endothelial interactions using intravital
microscopy inWKY-GFP bonemarrow chimeras.WKY-GFP bonemarrow
was harvested and injected into WKY wild-type recipients to create bone
marrow chimeras as previously described (Smith et al., 2007). Briefly,
femurs were harvested from WKY-GFP rats and bone marrow cells
collected under sterile conditions. Recipient WKY rats were irradiated
(8 Gy) and bone marrow cells (∼8×106) injected intravenously (i.v.). After
8 weeks, reconstitution was confirmed (data not shown) and kidneys imaged
under anaesthesia, after exposure of superficial kidney cortex from
surrounding tissue by careful blunt dissection. Images were taken using
SP5 confocal microscope with i.v. infusion of 70 kDa dextran-
tetramethylrhodamine (Invitrogen).
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